全文获取类型
收费全文 | 734篇 |
免费 | 57篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 38篇 |
妇产科学 | 7篇 |
基础医学 | 104篇 |
口腔科学 | 8篇 |
临床医学 | 38篇 |
内科学 | 88篇 |
皮肤病学 | 23篇 |
神经病学 | 164篇 |
特种医学 | 40篇 |
外科学 | 59篇 |
综合类 | 7篇 |
预防医学 | 18篇 |
眼科学 | 10篇 |
药学 | 85篇 |
中国医学 | 1篇 |
肿瘤学 | 67篇 |
出版年
2023年 | 3篇 |
2022年 | 3篇 |
2021年 | 15篇 |
2020年 | 19篇 |
2019年 | 24篇 |
2018年 | 30篇 |
2017年 | 28篇 |
2016年 | 30篇 |
2015年 | 21篇 |
2014年 | 27篇 |
2013年 | 33篇 |
2012年 | 43篇 |
2011年 | 35篇 |
2010年 | 21篇 |
2009年 | 14篇 |
2008年 | 32篇 |
2007年 | 42篇 |
2006年 | 42篇 |
2005年 | 52篇 |
2004年 | 46篇 |
2003年 | 41篇 |
2002年 | 19篇 |
2001年 | 24篇 |
2000年 | 25篇 |
1999年 | 22篇 |
1998年 | 10篇 |
1997年 | 3篇 |
1996年 | 5篇 |
1995年 | 5篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1990年 | 5篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1974年 | 3篇 |
1973年 | 5篇 |
1972年 | 3篇 |
1971年 | 5篇 |
1970年 | 1篇 |
1908年 | 1篇 |
排序方式: 共有791条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
Liver transplantation (LT) is a major surgery performed on patients with end stage liver disease. Nutrition is an integral part of patient care, and protein-energy malnutrition is almost universally present in patients suffering from liver disease undergoing LT. Nutrition assessment of preliver transplant phase helps to make a good nutrition care plan for the patients. Nutrition status has been associated with various factors which are related to the success of liver transplant such as morbidity, mortality, and length of hospital stay. To assess the nutritional status of preliver transplant patients, combinations of nutrition assessment methods should be used like subjective global assessment, Anthropometry mid arm-muscle circumference, Bioelectrical impedance analysis (BIA) and handgrip strength. 相似文献
6.
Monzr M. Al Malki Nitya Nathwani Dongyun Yang Saro Armenian Sanjeet Dadwal Jaroslava Salman Sally Mokhtari Thai Cao Karamjeet Sandhu Michelle Rouse Matthew Mei Haris Ali Pablo Parker Joseph Alvarnas Eileen Smith Margaret O. Donnell Guido Marcucci David Snyder Ryotaro Nakamura 《Biology of blood and marrow transplantation》2018,24(9):1828-1835
Allogeneic hematopoietic stem cell transplantation (alloHCT) is offered increasingly to elderly patients with hematologic malignancies. However, outcome data in those who are 70 years or older are limited, and no standard conditioning regimen has been established for this population. In this retrospective study we evaluated the outcome of 53 consecutive patients aged 70 years and older who underwent alloHCT with melphalan-based reduced-intensity conditioning (RIC) at City of Hope. Engraftment was prompt, with median time to neutrophil engraftment of 15 days. More than 95% of patients achieved complete donor chimerism within 6 weeks from HCT, consistent with the “semiablative” nature of this regimen. With a median follow-up of 31.1 months, the 2-year overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) were 68.9%, 63.8%, and 17.0%, respectively. Cumulative incidence of relapse at 1 and 2 years was 17.0% and 19.3%, respectively. One hundred–day cumulative incidence of grades II to IV acute graft-versus-host disease was 37.7% (grades III to IV, 18.9%), and 2-year cumulative incidence of chronic graft-versus-host disease was 61.9% (extensive, 45.9%). The only significant predictor for poor OS was high/very high disease risk index. Transplant-related complications and morbidities observed here did not differ from the commonly expected in younger patients treated with RIC. In conclusion, alloHCT with a melphalan-based conditioning regimen is associated with acceptable toxicities and NRM, lower incidence of relapse, and favorable OS and PFS in patients aged 70 years or older. 相似文献
7.
Jyoti Bakshi Beatriz Tejera Segura Christopher Wincup Anisur Rahman 《Clinical reviews in allergy & immunology》2018,55(3):352-367
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a prevalence of approximately 1 in 1000. Over the last 30 years, advances in treatment such as use of corticosteroids and immunosuppressants have improved life expectancy and quality of life for patients with lupus and the key unmet needs have therefore changed. With the reduced mortality from disease activity, development of cardiovascular disease (CVD) has become an increasingly important cause of death in patients with SLE. The increased CVD risk in these patients is partly, but not fully explained by standard risk factors, and abnormalities in the immune response to lipids may play a role. Invariant natural killer T cells, which are triggered specifically by lipid antigens, may protect against progression of subclinical atherosclerosis. However, currently our recommendation is that clinicians should focus on optimal management of standard CVD risk factors such as smoking, blood pressure and lipid levels. Fatigue is one of the most common and most limiting symptoms suffered by patients with SLE. The cause of fatigue is multifactorial and disease activity does not explain this symptom. Consequently, therapies directed towards reducing inflammation and disease activity do not reliably reduce fatigue and new approaches are needed. Currently, we recommend asking about sleep pattern, optimising pain relief and excluding other causes of fatigue such as anaemia and metabolic disturbances. For the subgroup of patients whose disease activity is not fully controlled by standard treatment regimes, a range of different biologic agents have been proposed and subjected to clinical trials. Many of these trials have given disappointing results, though belimumab, which targets B lymphocytes, did meet its primary endpoint. New biologics targeting B cells, T cells or cytokines (especially interferon) are still going through trials raising the hope that novel therapies for patients with refractory SLE may be available soon. 相似文献
8.
Tekok-Kilic A Benedict RH Weinstock-Guttman B Dwyer MG Carone D Srinivasaraghavan B Yella V Abdelrahman N Munschauer F Bakshi R Zivadinov R 《NeuroImage》2007,36(4):1294-1300
The primary goal of this study was to investigate associations between regional gray matter (GM) atrophy and neuropsychological function in multiple sclerosis (MS), while accounting for the influence of central brain atrophy (i.e. third ventricle enlargement). Using a cross-sectional design, we studied 59 MS patients with brain MRI and neuropsychological testing. Regional gray matter fractions (rGMFs) were calculated from MRI images for 11 homologous brain areas using the semiautomatic brain region extraction (SABRE) technique. Neuropsychological testing followed consensus panel guidelines and included tests emphasizing episodic memory, working memory and processing speed. The analytic approach was stepwise linear regression, with forward selection and p<0.05 threshold for significance. Consistent with previous research, there were significant correlations between third ventricle width and neuropsychological tests. Stepwise linear regression analyses controlling for third ventricle width retained rGMFs obtained from specific regions within the prefrontal cortex. Left frontal atrophy was associated with tests emphasizing auditory/verbal memory. Right frontal atrophy was associated with impairment in visual episodic and working memory. For the first time, we show an independent relationship between cortical atrophy and cognitive impairment after accounting for the effects of central atrophy. 相似文献
9.
10.
Corpus Callosum Atrophy Correlates with Gray Matter Atrophy in Patients with Multiple Sclerosis 下载免费PDF全文